Name

Cobio Diagnostics

Legal name

Cobio Diagnostics, Inc.

Website

https://cobio.co

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Cobio Diagnostics is a Colorado-based pre-commercial biotech developing a phage-amplified diagnostic platform for same-shift phenotypic bacterial identification and antimicrobial susceptibility testing, serving hospital labs, public health agencies, and resource-limited healthcare settings.

Ownership category

akta.pro rank

Product category

Clinical Microbiology / In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC)

akta.pro secondary industries

Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

• Bacterial identification diagnostics
• Antimicrobial susceptibility testing
• Phenotypic diagnostic platform
• Bacteriophage-based diagnostics
• Rapid pathogen detection

Headquarters

HQ city

Golden

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Diagnostic Platform (Pre-Commercial): Company is in pre-commercial development stage. No revenue has been generated. All technologies are currently in pre-commercial development. Future revenue model will likely involve sale of diagnostic tests/kits and potentially instruments.

Go-to-market motion1 record

Marketing channels2 records

Core offering

Cobio Diagnostics is developing a next-generation, phage-amplified diagnostic platform that uses species-specific lytic bacteriophage formulations to deliver rapid bacterial identification, antimicrobial susceptibility testing (AST), and minimum inhibitory concentration (MIC) determination directly from clinical specimens in a single work shift. The phenotypic, instrument-agnostic platform supports multiple downstream readouts including MALDI-TOF mass spectrometry, Oxford Nanopore MinION sequencing, and immunoassay-based detection, and is designed to scale across pathogens and healthcare environments from advanced clinical laboratories to resource-limited settings. All technologies are currently in pre-commercial development.

Product overview

Cobio Diagnostics offers a single, unified phage-amplified diagnostic platform that delivers rapid phenotypic bacterial identification, antimicrobial susceptibility testing (AST), and minimum inhibitory concentration (MIC) determination directly from clinical specimens. The platform is modular, supporting multiple downstream detection readouts including MALDI-TOF Mass Spectrometry, Nanopore Adaptive Sequencing (via MinION sequencers), and Immunoassay-based methods. The same underlying phage biology supports these flexible analytical readouts and deployment models. All technologies are currently in pre-commercial development.

Differentiator

Problem solved

Functional benefit

Products and services

• Phage-Amplified Diagnostic Platform A next-generation, phenotypic diagnostic platform that harnesses the specificity and amplification power of species-specific lytic bacteriophages to deliver rapid bacterial identification, antimicrobial susceptibility testing, and minimum inhibitory concentration determination directly from clinical specimens in a single work shift. Designed for clinical microbiology laboratories and resource-limited settings. Currently in pre-commercial development.

Quantifiable outcome

• Time to results reduced from 18-72 hours (conventional culture) to as little as 2 hours
• +2 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability2 records

Feature6 records

Partnerships

Two partnerships are on record, tiered minor.

• University of ColoradominorStrategic or Co-development PartnerInfectious disease physicians from University of Colorado serve on Cobio's Advisory Team, providing clinical expertise and input on R&D priorities.
• The Children's Hospital of ColoradominorStrategic or Co-development PartnerInfectious disease physicians from The Children's Hospital of Colorado serve on Cobio's Advisory Team, providing clinical expertise and input on R&D priorities.

Scale indicators4 records

Recent moves5 records

Expansion highlights3 records

Direct peers

• T2 Biosystems: Developer of T2Bacteria and related direct-from-blood rapid bacterial diagnostics for sepsis-relevant pathogens. Same end-customers (hospital labs, stewardship programs) and same unmet need (rapid phenotypic ID without waiting for culture).
• Specific Diagnostics (a bioMérieux company): Specific Diagnostics built a phenotype-based rapid AST platform acquired by bioMérieux, validating the commercial strategic logic of phenotypic rapid AST and representing the most direct peer in technology and category.
• Accelerate Diagnostics: Commercial-stage developer of the Accelerate Pheno system, which delivers rapid phenotypic bacterial ID and AST directly from positive blood cultures in hours. Direct head-to-head competitor to Cobio's same-shift ID/AST value proposition targeting hospital microbiology labs.

Broad incumbents

• Cepheid (Danaher): Leader in rapid molecular diagnostics (GeneXpert) deployed widely across hospital core labs. Competes on workflow integration and speed though the technology is genotypic rather than phenotypic; sets the standard for what 'same-shift' acceptance looks like in U.S. labs.
• Becton Dickinson (BD): BD Phoenix M50 and related diagnostic systems provide automated ID/AST in clinical microbiology. Broad incumbent and potential partner for scale-out of any new rapid phenotypic test reaching FDA clearance.
• Bruker (MALDI Biotyper): Incumbent in clinical MALDI-TOF mass spectrometry identification (MALDI Biotyper), which Cobio's platform is explicitly designed to integrate with. Represents both an opportunity (channel partner for Cobio's MALDI detection module) and a competitive threat if Bruker extends to its own rapid phenotypic AST.
• bioMérieux (BioFire/VITEK): Dominant incumbent in clinical microbiology with VITEK 2 for AST, BioFire FilmArray syndromic panels, and now Specific Diagnostics. Cobio's modular immunoassay/MALDI workflows are designed to integrate into this existing installed base, making bioMérieux both a competitor and a potential partner.

Emerging players

• Selux Diagnostics: Developer of rapid phenotypic AST platform (Next Generation Phenotyping) targeting bloodstream infections. Closely analogous to Cobio in technology philosophy and target indication, though at a different stage of platform maturity.
• Pattern Bioscience: Developer of rapid phenotypic ID/AST technology targeting bloodstream infections. Closely comparable in scientific approach (single-cell phenotypic readouts) and target customer; smaller scale than incumbents and at similar commercialization stage to Cobio.
• Qvella: Early-stage developer of rapid ID/AST directly from clinical specimens without culture. Technologically adjacent — both aim to collapse the 18-72 hour culture window and serve the same hospital microbiology buyer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cobio Diagnostics